| Literature DB >> 26512730 |
Jeffrey D Rudolf1, Lance Bigelow2, Changsoo Chang2, Marianne E Cuff2, Jeremy R Lohman1, Chin-Yuan Chang1, Ming Ma1, Dong Yang1, Shonda Clancy2, Gyorgy Babnigg2, Andrzej Joachimiak2, George N Phillips3, Ben Shen1,4,5.
Abstract
The bleomycins (BLMs), tallysomycins (TLMs), phleomycin, and zorbamycin (ZBM) are members of the BLM family of glycopeptide-derived antitumor antibiotics. The BLM-producing Streptomyces verticillus ATCC15003 and the TLM-producing Streptoalloteichus hindustanus E465-94 ATCC31158 both possess at least two self-resistance elements, an N-acetyltransferase and a binding protein. The N-acetyltransferase provides resistance by disrupting the metal-binding domain of the antibiotic that is required for activity, while the binding protein confers resistance by sequestering the metal-bound antibiotic and preventing drug activation via molecular oxygen. We recently established that the ZBM producer, Streptomyces flavoviridis ATCC21892, lacks the N-acetyltransferase resistance gene and that the ZBM-binding protein, ZbmA, is sufficient to confer resistance in the producing strain. To investigate the resistance mechanism attributed to ZbmA, we determined the crystal structures of apo and Cu(II)-ZBM-bound ZbmA at high resolutions of 1.90 and 1.65 Å, respectively. A comparison and contrast with other structurally characterized members of the BLM-binding protein family revealed key differences in the protein-ligand binding environment that fine-tunes the ability of ZbmA to sequester metal-bound ZBM and supports drug sequestration as the primary resistance mechanism in the producing organisms of the BLM family of antitumor antibiotics.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26512730 PMCID: PMC4809751 DOI: 10.1021/acs.biochem.5b01008
Source DB: PubMed Journal: Biochemistry ISSN: 0006-2960 Impact factor: 3.162